BeyondSpring Inc. BYSI
Biotechnology: Pharmaceutical Preparations · IPO 2017 · data as of November 13, 2026
BeyondSpring Inc. (BYSI) is a healthcare company listed in the US with a market value of about $25M.
Its overall Stock Analiz score is 0.2 out of 5 (weak). The strongest part is financial health (1/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of -100% a year, a 5-year average ROIC of -173%.
About BeyondSpring
BeyondSpring is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2017. It was profitable in 0 of the last 10 years in our data.
Score: 0.2 / 5
Checks passed
- More cash than debt, or low debt to equity
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $1M | $1M | $180000 | $0 | $0 | $0 | $0 |
| Net income | -$1M | -$11M | -$21M | -$33M | -$64M | -$61M | -$38M | -$55M | -$92M | -$12M |
| Free cash flow | -$20M | -$17M | -$17M | -$27M | -$50M | -$44M | -$48M | -$40M | -$29M | -$14M |
| EPS (diluted) | $-0.02 | $-0.27 | $-0.51 | $-0.81 | $-1.56 | $-1.48 | $-0.93 | $-1.33 | $-2.23 | $-0.29 |
| Net margin | — | — | — | -2463.3% | -4750.5% | -33873.9% | — | — | — | — |
| ROIC | — | — | — | — | -172.9% | -69.3% | -117.9% | — | -285.9% | -80.4% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does BeyondSpring pay a dividend?
Not currently.
Is BeyondSpring a good stock to buy?
We do not give buy or sell advice. BeyondSpring scores 0.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.